Results 21 to 30 of about 6,021 (252)

Refractory pityriasis rubra pilaris treated with abrocitinib [PDF]

Dermatology Reports
Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts the quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor
Filip Rob
doaj   +2 more sources

A Rare Post-infectious Rash: Pityriasis Rubra Pilaris After COVID-19 Infection. [PDF]

Cureus, 2023
Pityriasis rubra pilaris (PRP) is a rare papulosquamous skin disorder that often presents with erythematous follicular-based hyperkeratotic papules that can become confluent and lead to erythroderma and electrolyte and thermoregulatory imbalances ...
Duncan P, Flood D, Dietz C.
europepmc   +2 more sources

Patients with keratinization disorders due to ABCA12 variants showing pityriasis rubra pilaris phenotypes [PDF]

Journal of dermatology (Print), 2023
Pathogenic variants in ABCA12 are important causative genetic defects for autosomal recessive congenital ichthyoses (ARCI), which include congenital ichthyosiform erythroderma (CIE), harlequin ichthyosis, and lamellar ichthyosis.
Akiyama, Masashi, Hamada, Takahiro, Ishii, Norito, Ito, Yasutoshi, Kawaguchi, Aya, Kobashi, Haruka, Koga, Hiroshi, Muro, Yoshinao, Nakama, Takekuni, Ogi, Tomoo, Takeichi, Takuya, Yamamoto, Mayuko, Yoshikawa, Takenori   +12 more
core   +2 more sources

Misdiagnosed Pityriasis Rubra Pilaris Successfully Managed With Isotretinoin: A Case Series. [PDF]

Cureus, 2023
Being a rare inflammatory, hyperproliferative dermatosis, diagnosing pityriasis rubra pilaris (PRP) can be a challenge to many clinicians. Our case reports aim to demonstrate that PRP is frequently diagnosed and managed as atopic dermatitis (AD) and that
Al Khalifa N, Alsabbagh M, Raees M, Aljufairi E.   +3 more
europepmc   +2 more sources

A Review of Pityriasis Rubra Pilaris and Rheumatologic Associations [PDF]

Clinical and Developmental Immunology, 2004
Pityriasis rubra pilaris (PRP) is a rare group of hyperkeratotic, papulosquamous disease that can be acquired or inherited. There have been reported cases of rheumatologic associations, mainly arthritis and ...
Happy Chan, Fu Tong Liu, Stanley Naguwa   +2 more
doaj   +5 more sources

Successful treatment with cyclosporine and guselkumab for pityriasis rubra pilaris [PDF]

Clinical Case Reports, 2022
A man with pityriasis rubra pilaris (PRP) showed no improvement in skin symptoms despite treatment with several drugs. The patient was diagnosed as having type 1 PRP. Combination therapy with cyclosporine and guselkumab improved his skin condition. Here,
Mai Nishimura, Makoto Kondo, Koji Habe, Akinobu Hayashi, Keiichi Yamanaka   +4 more
doaj   +2 more sources

Pityriasis Rubra Pilaris [PDF]

Proceedings of the Royal Society of Medicine, 1933
Godfrey Bamber
  +8 more sources

Pityriasis Rubra Pilaris

Journal of the American Academy of Dermatology
Greiling TM, Brown F, Syed HA.
europepmc   +4 more sources

Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial.

JAMA Dermatol
Importance There is no US Food and Drug Administration-approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options.
Velasco RC, Shao C, Cutler B, Strunck J, Kent G, Cassidy PB, Choate K, Greiling TM.   +7 more
europepmc   +2 more sources

A case of pityriasis rubra pilaris secondary to ponatinib [PDF]

SAGE Open Medical Case Reports
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting ...
Ariana Nateghi, Florence Lagacé-Thomassin, Julie Desrochers   +2 more
doaj   +2 more sources